JP2009529541A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529541A5
JP2009529541A5 JP2008558554A JP2008558554A JP2009529541A5 JP 2009529541 A5 JP2009529541 A5 JP 2009529541A5 JP 2008558554 A JP2008558554 A JP 2008558554A JP 2008558554 A JP2008558554 A JP 2008558554A JP 2009529541 A5 JP2009529541 A5 JP 2009529541A5
Authority
JP
Japan
Prior art keywords
group
treatment
prevention
pharmaceutical formulation
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/063699 external-priority patent/WO2007104053A2/en
Publication of JP2009529541A publication Critical patent/JP2009529541A/ja
Publication of JP2009529541A5 publication Critical patent/JP2009529541A5/ja
Pending legal-status Critical Current

Links

JP2008558554A 2006-03-09 2007-03-09 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤 Pending JP2009529541A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78080006P 2006-03-09 2006-03-09
PCT/US2007/063699 WO2007104053A2 (en) 2006-03-09 2007-03-09 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009529541A JP2009529541A (ja) 2009-08-20
JP2009529541A5 true JP2009529541A5 (enExample) 2010-04-30

Family

ID=38371082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558554A Pending JP2009529541A (ja) 2006-03-09 2007-03-09 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤

Country Status (12)

Country Link
US (2) US7951803B2 (enExample)
EP (1) EP1991547A2 (enExample)
JP (1) JP2009529541A (enExample)
KR (1) KR20080107466A (enExample)
CN (1) CN101454325A (enExample)
AU (1) AU2007222982A1 (enExample)
BR (1) BRPI0709007A2 (enExample)
CA (1) CA2646429A1 (enExample)
EA (1) EA014907B1 (enExample)
MX (1) MX2008011525A (enExample)
WO (1) WO2007104053A2 (enExample)
ZA (1) ZA200807715B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AU2007309167A1 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as PKC-theta inhibitors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
JP2013519719A (ja) * 2010-02-18 2013-05-30 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） トリアゾロ［４，５−ｂ］ピリジン誘導体
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JP6306035B2 (ja) 2012-11-09 2018-04-04 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシミン置換キナゾリン
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US10093660B2 (en) 2013-12-04 2018-10-09 Evotec Internatonal Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
JP6479854B2 (ja) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシイミン置換キナゾリン
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
CN106008506B (zh) * 2016-06-27 2018-02-13 山东大学 取代嘌呤类衍生物及其制备方法与应用
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US20250289806A1 (en) * 2022-04-28 2025-09-18 University Of Miami Compounds for proliferative disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
JP4249804B2 (ja) 1995-04-03 2009-04-08 ノバルティス・アクチエンゲゼルシャフト ピラゾール誘導体およびその製造法
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
WO2003006465A1 (en) * 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors
AU2002363175A1 (en) 2001-10-29 2003-05-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
US7105526B2 (en) * 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JP5704785B2 (ja) * 2004-07-19 2015-04-22 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫抑制のためのｆｌｔ３阻害剤
BRPI0517272A (pt) * 2004-10-29 2008-10-07 Tibotec Pharm Ltd derivados de pirimidina bicìclicos de inibição de hiv
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
BRPI0610514A2 (pt) * 2005-04-05 2016-11-16 Pharmacopeia Inc composto, composição farmacêutica, e, método de tratamento de um distúrbio
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AU2007309167A1 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as PKC-theta inhibitors
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US20080220256A1 (en) * 2007-03-09 2008-09-11 Ues, Inc. Methods of coating carbon/carbon composite structures

Similar Documents

Publication Publication Date Title
JP2013525444A5 (enExample)
WO2007131005A3 (en) Use of organic compounds
JP2017527578A5 (enExample)
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
WO2012094636A3 (en) Chemosensory receptor ligand-based therapies
JP2010518061A5 (enExample)
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
JP2011527332A5 (enExample)
JP2017526711A5 (enExample)
JP2009530399A5 (enExample)
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
JP2013529210A5 (enExample)
JP2016040288A5 (enExample)
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
WO2010003624A3 (en) Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP2012507535A5 (enExample)
JP2014505107A5 (enExample)
JP2012255002A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
EP2579876A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDICT
JP2006525297A5 (enExample)
JP2014510741A5 (enExample)
JP2018502135A5 (enExample)